ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
DUBLIN, Ireland, April 09, 2018 -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its first-quarter financial results will be released on Wednesday, May 9, 2018. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and replay may be accessed at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes before the live webcast to ensure adequate time for any software download that may be needed to access the webcast.
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Investors:
Tina Ventura
Senior Vice President,
Investor Relations
[email protected]
Ruth Venning
Executive Director,
Investor Relations
[email protected]
U.S. Media:
Geoff Curtis
Senior Vice President,
Corporate Affairs & Chief Communications Officer
[email protected]
Ireland Media:
Ray Gordon
Gordon MRM
[email protected]
